Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study

STOCKHOLM, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the d... Biopharmaceuticals, Oncology Medivir, remetinostat, cutaneous T-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news